RÉPUBLIQUE FRANÇAISE
Liberté Égalité Fraternité

Inserm
La science pour la santé
From science to health

HR EXCELLENCE IN RESEARCH

CALL FOR APPLICATION

INSERM CHAIR Recruitment

Immunothrombosis and cardiovascular diseases: identification of key targets for innovative therapies

The Inserm chair recruitments opened to Inserm are intended for researchers with strong potential to manage and lead research teams and participate in national, European or international projects.

This recruitment, based on research and teaching projects, is aimed at researchers with a doctorate or equivalent and a first post-doctoral experience. The position is offered on a fixed-term contract (CDD) with a view to tenure in the Inserm Research Directors personnel at the end of the contract.

How apply: https://pro.inserm.fr

Supporting institution:	Inserm : Institut national de la Santé et de la recherche médicale
Name of the head of the institution:	Pr. Didier Samuel
Academic region:	PARIS
Location/ Site concerned:	INSERM U1176 - Hemostasis, inflammation, thrombosis
Partner institution:	Paris-Saclay University
Research contact:	Cécile DENIS : cecile.denis@inserm.fr
Administrative contact:	chaires-professeur-junior@inserm.fr
Research fields EURAXESS:	Cardio-vascular (Medical Science)
Keywords:	Immunothrombosis, Hemostasis, Inflammation, Nanobodies, Cardiovascular diseases.

Job title to be filled:	Chaire - Immunothrombosis and cardiovascular diseases: identification of key targets for innovative therapies
Body after tenure:	Research Director

Anticipated duration of the contract:	years
Scientific domains/fields:	Biology and Health
Corresponding specialized scientific commissions (CSS):	Physiology and pathophysiology of major systems – CSS3
Project name:	Immunothrombosis and cardiovascular diseases: identification of key targets for innovative therapies

Remuneration package	3 500€ - 5 000€ according to research experience
Quota	Full Time

Strategy of the host institution:

The French National Institute for Health and Medical Research (INSERM) is the primary public institution dedicated to biomedical and health research. Inserm conducts research with a focus on translating research findings into clinical and therapeutic applications that address current public health challenges. Partners include universities, hospitals, and international research organizations.

One of Inserm's priorities in its 2025 strategic plan (priority 1, objective 2) is to promote disruptive research. The recruitment of a young researcher with high potential is part of this approach. The recipient will energize and bring a new dimension to the host laboratory's research project while building on a solid pre-existing foundation.

Above all, this recruitment is intended to open the Research Unit's activities to the international arena, as recommended by Inserm (priority 2, objective 5 of the strategic plan). Applying for European funding such as ERC grants will be one of the host laboratory's priorities through this CPJ.

The CPJ program at Inserm has already received positive feedback and has been deemed beneficial for the laboratories that have participated in it. In this specific case, by promoting recruitment on site and for a given project, this CPJ will meet the immediate needs of the host laboratory by enabling it to take the next step in its European expansion.

Strategy of the host laboratory:

Inserm UMRS 1176 focuses on the study of hemostasis and thrombosis mechanisms. Thanks to its cutting-edge expertise in the coagulation cascade and its cellular and molecular actors, such as blood platelets and pro- and anti-coagulant molecules, the Unit has contributed to improving knowledge in the field of hemorrhagic diseases, as well as in the role played by these determinants in various processes beyond hemostasis (cancer, sepsis, etc.). The project is in line with the Unit's theme, while allowing it to broaden its focus beyond rare diseases to wider public health issues and to create synergy between the Unit's researchers' skills and their application in the field of cardiovascular diseases. The recruitment of a high-level researcher will also ensure the sustainability of the Research Unit by strengthening human potential and renewing management positions.

Summary of the scientific project:

Immunothrombosis, or the interaction between immune responses and coagulation, contributes to cardiovascular disease by promoting microvascular thrombosis, inflammation, and endothelial dysfunction. Despite the widespread use of antiplatelet drugs, which target only some of the mechanisms involved, this process continues to affect patients, revealing the limitations of current therapies. Infections significantly increase the risk and severity of cardiovascular disease, probably by enhancing immunothrombosis, although the exact mechanisms remain unclear. The main objective is to identify the mediators that drive this immunothrombotic cascade among the cellular and molecular actors of haemostasis. The long-term goal is to develop strategies capable of targeting certain elements, for example via nanobodies, to neutralize inflammation-induced thrombosis while preserving haemostasis.

Summary of the teaching project:

The teaching project will focus on haemostasis, vascular pathophysiology, and immunothrombosis in several master's programs at Paris-Saclay University and Paris-Cité University. The candidate will organize and participate in teaching units on immunohematology within the Master's 1 and Master's 2 international programs in "Drug and Health Product Development (D2HP, D. Bonte and S. Tfaili), which is taught in English, teaching units on haemostasis within the Master 2 program in Biology for Innovative Therapies and Diagnostics (BioInnov, G. Schlecht Louf and N. Chaput), and the Master 2 program in Cardiovascular Sciences (M2SC, D. Faille, G. Caligiuri, and JS. Silvestre). The candidate will also supervise practical sessions on communication in research within the Master 2 program in Pharmaceutical Biotechnology and Innovative Therapies (BPTI, C. Smadja and I Turbica).

National Research Agency package:	200k€
Other package:	0k€
Co-funding*	

*source et montant

Scientific dissemination/ Open Science:

Scientific communication and dissemination: Within the framework of the CPJ, we aim for broad, impactful, and open scientific dissemination to maximize the project's impact, promote its results, and ensure tenure.
The foundation will remain publications, which are still the most crucial deliverables, such as 1) research articles published in leading top-tier international journals with high impact, 2) review and perspective articles on the state of the art, particularly on the exact mechanisms of immunothrombosis, which are still poorly defined, or on innovative therapeutic strategies (nanobodies). This will establish the CPJ's recognition as an expert in the field. 3) The publication of articles detailing the methodologies and experimental protocols developed by the team, ensuring the reproducibility of results.
Active participation in conferences through oral or poster presentations on submitted abstracts or invited lectures, as well as participation in webinars (collaboration with the ISTH), will be crucial

for reaching a wider audience in the field and enhancing the international visibility of the CPJ recipient.
Finally, scientific dissemination will also involve the transfer of knowledge through the training of doctoral and postdoctoral students and university teaching.
Open Science: We are committed to systematically depositing the final version of all our scientific publications accepted by the publisher in an open institutional or national archive, such as HAL. Publications will be made immediately available in open access (Open Access Gold or Green without embargo), in accordance with the requirements of Plan S and the French National Research Agency (ANR).
A detailed Data Management Plan (DMP) will be drawn up at the start of the project, using the DMP Opidor tool, to describe the collection, storage, preservation, and dissemination of primary and secondary data.
We will adhere to the FAIR principles (Findable, Accessible, Interoperable, Reusable) for the data produced.
Science and society: The aim is to raise awareness of the challenges of immunothrombosis and the importance of developing new targeted therapies. We aim to demonstrate the societal impact of the project and communicate with society about the challenges in terms of public health.
This communication will take place through the following channels:
1) Participation in national and international events: at Science Festivals, by organizing interactive workshops on the theme of blood and inflammation; on World Thrombosis Day, by participating in stands to inform the public about risk factors related to infections and thrombosis.
2) Social media and websites: Creation of a page dedicated to the project on the research unit's website; regular communications on the unit's LinkedIn page. Participation in the dissemination of information via the IHU PROMETHEUS website (currently being finalized), which is open to the public and on which an immunothrombosis focus will be identified.
3) Creation of educational capsules on immunothrombosis as part of PROMETHEUS on severe sepsis.

Indicators:

The monitoring indicators and methodology will reflect the three main areas of focus of a CPJ's role: Research, Teaching/Training, and Outreach/Impact.
Research evaluation will focus on the progress of the scientific project, the high quality of the results, and financial autonomy. Scientific output will be monitored by the number and quality of publications. Funding will be monitored by the amount of funds raised and the diversity of funding sources.
Teaching activity will be monitored by the number of teaching hours completed, and the number of applications and foreign interns or post-doctoral students accepted, which will testify to the attractiveness of the programs.
The monitoring indicators for integration and influence will be based on involvement in the laboratory's tasks of collective interest, the number of active collaborations, and the filing of any patents.
In terms of methodology, an advisory committee will be set up, consisting of the unit director assisted by two senior researchers from the laboratory and a member from outside the laboratory, ideally international. An annual activity report will be prepared by the CPJ recipient to describe the achievement of intermediate objectives in relation to the initial timetable. During the

third year, the CPJ recipient will be interviewed by the Monitoring Committee to validate the trajectory and adjust the objectives if necessary.

Selection of candidates:

It is expected the recruited researcher to become rapidly a group leader in the GAD team. So the candidate should demonstrate ability to supervise Ph.D students, post-doctoral fellow and technical support staff. She/he should have the capacity to obtain competitive funding to manage her/his group.

Successful candidates are chosen by a selection commission composed of six to ten members, the majority of whom are specialists in the fields of research concerned.

The commission carries out an initial examination of the applications, focused in particular on candidate experience and skills relative to the research and teaching project presented above. A shortlist of candidates is then selected for interview.
Only candidates selected by the selection committee on the basis of their applications will be invited to interview.

The interviews are followed by a deliberation during which selection commission will discuss the quality, originality and, where appropriate, the interdisciplinarity of the research and teaching projects presented by the candidates, their motivation and their scientific and teaching supervision capacity.

The candidates selected at the end of the selection process will be offered a researcher contract, following approval from the President and CEO of Inserm.

Required profile:

Education Level**: Phd**

Researcher Profile: R3/R4

R3 Established researcher A stage in a researcher's career describing those who have developed a level of independence and can described as an established researcher
R4 Leading Research A stage in a researcher's career where they can be termed a 'leading researcher'. This would include the team leader of a research group or head of an industry R&D laboratory.

Your application will be evaluated according to the following criteria :

- Relevance and originality of the project related to the research field
- International exposure in research projects
- Your ability to raise funds
- Participation in editorial and reviewing activities
- Your teaching experience
- Your ability to lead a team…

Application instruction:

Applications can be submitted online at EVA.
Deadline application: **September 2, 2026**

Please complete the scientific file in English.

It is imperative to contact the laboratory corresponding to the Chair you have applied for in order to build the project with them.

Position also open to 'Bénéficiaires de l'Obligation d'Emploi' (disabled persons), as defined in article 27 of law no. 84-16 of January 11, 1984 on statutory provisions for the civil service.